A growing body of research highlights high discontinuation rates of semaglutide among adults, especially the elderly, driven by side effects, cost, and muscle health concerns. Strategies to ensure safe, sustained use are increasingly emphasised.
A growing body of research suggests that many people who start semaglutide for weight loss do not remain on it for a full year, and that pattern appears to be driven less by motivation than by practical barriers. A Danish registry study of 77,310 adults found that 52% had stopped within 12 months, with drop-off building steadily over time rather than arriving all at once, while a separate US analysis of 125,474 adults reported similarly high discontinuation rates, especially among those without diabetes. The findings help explain why older adults often need a plan not just for starting treatment, but for staying on it, adjusting it or ending it safely.
The most common reason people stop is side effects, particularly nausea, reflux, constipation and fatigue, which often flare when doses rise. Cost is another major factor, and the problem becomes sharper around age 65, when coverage can change and affordability can suddenly become the deciding issue. Research also points to a concern that matters especially in later life: some of the weight lost on GLP-1 drugs is lean tissue as well as fat, and older adults already face age-related muscle decline. Evidence on how much strength is affected remains mixed, but the practical response is consistent: adequate protein, resistance exercise and body-composition monitoring matter more, not less, as people age.
Another key issue is what happens after stopping. Follow-up from the STEP 1 trial extension found that participants regained about two-thirds of their lost weight within a year of discontinuing semaglutide, reinforcing the idea that obesity often behaves like a chronic condition rather than a short-term project. A 2026 Bayesian re-analysis of six studies, published in eClinicalMedicine, estimated a monthly regain rate of 1.04 kg after treatment ends, adding to concerns that stopping without a maintenance strategy can rapidly erase earlier progress. For older adults, that can be especially costly if it means losing muscle while regaining fat.
For that reason, clinicians say supervised treatment should anticipate the most common points of failure. Slower dose increases, temporary dose holds, hydration support, regular laboratory checks and early follow-up can help people tolerate treatment better, while strength training and nutrition guidance can reduce the risk of unwanted muscle loss. The article also notes that some patients stop because they believe they have reached their goal, even though a maintenance plan may still be needed. In those cases, the best approach is usually to review symptoms, body composition, cost and long-term goals before making any change.
Stopping can still be the right decision when side effects remain intolerable, complications develop, muscle function worsens despite intervention, or cost makes treatment unsustainable. But researchers and clinicians increasingly agree that the worst outcome is a quiet, unsupported stop. For older adults weighing GLP-1 treatment, the question is not only whether to begin, but how to continue with eyes open, and how to leave the drug safely if that becomes the right choice.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
